HBK Investments’s Epizyme, Inc EPZM Stock Holding History

HBK Investments’s Portfolio EPZM Stock Details EPZM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-35,737	Closed	-$443K	–	1141
2019 Q1	$443K	Buy	35,737 +17,561	+97%	+$196K	﹤0.01%	852
2018 Q4	$112K	Buy	+18,176	New	+$139K	﹤0.01%	1154
2018 Q3	–	Sell	-64,760	Closed	-$877K	–	1396
2018 Q2	$877K	Buy	+64,760	New	+$1.01M	0.01%	667
2017 Q4	–	Sell	-11,600	Closed	-$221K	–	1182
2017 Q3	$221K	Sell	11,600 -55,454	-83%	-$846K	﹤0.01%	947
2017 Q2	$1.01M	Buy	+67,054	New	+$1.01M	0.01%	564
2016 Q2	–	Sell	-12,300	Closed	-$149K	–	1124
2016 Q1	$149K	Buy	+12,300	New	+$124K	﹤0.01%	911

Other funds holding EPZM

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

HBK Investments's EPZM Position: Q2 2019 in Review

HBK Investments sold out of Epizyme, Inc (EPZM) in Q2 2019, closing a stake of 35,737 shares — an estimated $443K sold.

HBK Investments first reported a position in EPZM in Q1 2016 and held it in 6 quarters. The position peaked at $1.01M in Q2 2017. 134 funds tracked by Wall St. Rank hold EPZM as of Q2 2019.

HBK Investments reported no remaining Epizyme, Inc position as of Q2 2019 after selling out during the quarter.
HBK Investments sold 35,737 Epizyme, Inc shares in Q2 2019, an estimated $443K.
HBK Investments first reported a position in Epizyme, Inc in Q1 2016 and held it in 6 quarters.
HBK Investments's Epizyme, Inc position peaked at $1.01M in Q2 2017.
134 funds tracked by Wall St. Rank held Epizyme, Inc as of Q2 2019.

Based on HBK Investments's 13F filing for Q2 2019, filed 14 Aug 2019.